Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: a UK cross-sectional survey
Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: a UK cross-sectional survey
复制标题
DOI：
10.1007/s00520-012-1548-y
复制
发表时间：
2013-02-01
影响因子：
3.1
通讯作者：
Lloyd, A. J.
中科院分区：
文献类型：
--
作者：
Acaster, S.;Gaugris, S.;Lloyd, A. J.
虽然已经报道了各种治疗对骨髓瘤患者健康相关生活质量（HRQL）的影响，但目前尚不清楚无治疗间期（TFI）的影响。本研究的目的是评估（1）TFI与其他治疗阶段相比是否与更好的HRQL相关，以及（2）TFI的长度是否影响HRQL。在英国进行了一项横断面邮政调查。该调查通过慈善机构Myeloma UK发送给605名多发性骨髓瘤患者，并要求患者使用欧洲癌症研究和治疗组织（EORTC）生活质量问卷核心30（QLQ-C30），EORTC QLQ-MY 20和EQ-5D对他们的HRQL进行评分。使用普通最小二乘回归分析结果。返回402份（67%）调查; 370份（61%）被认为符合分析条件。结果表明，相对于其他治疗阶段，第一次TFI和经历较长的TFI与QLQ-C30、MY 20和EQ-5D的各个领域评估的更好的HRQL显著相关。TFI的长度也对HRQL产生积极影响。这些信息对患者及其医生做出治疗决策可能很重要，包括扩展治疗的治疗方案的影响。
While the impact of various treatments on myeloma patients' health-related quality of life (HRQL) has been reported, the impact of a treatment-free interval (TFI) is currently unclear. The aims of this study were to assess if (1) a TFI is associated with a better HRQL vs. other treatment phases and (2) the length of the TFI influences HRQL.A cross-sectional postal survey was conducted in the UK. The survey was sent to 605 multiple myeloma patients via the charity Myeloma UK and asked patients to rate their HRQL using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30), EORTC QLQ-MY20 and the EQ-5D. The results were analysed using ordinary least squares regression.Surveys of 402 (67 %) were returned; 370 (61 %) were considered eligible for analysis. Results demonstrated that being in a first TFI relative to other treatment phases and experiencing a longer TFI were significantly associated with better HRQL as assessed by various domains of the QLQ-C30, MY20 and EQ-5D.Patients enjoy better HRQL when in their first TFI, and the length of the TFI also positively impacts on HRQL This information may be important for patients and their physicians making treatment decisions and has implications for treatment protocols incorporating extended therapy.